{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:44:58Z","timestamp":1778546698560,"version":"3.51.4"},"reference-count":56,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2019,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To perform patient preference-based comparative effectiveness and cost-utility (cost-effectiveness) analyses to evaluate topical bimatoprost 0.01%, latanoprost 0.005%, travoprost 0.004%, tafluprost 0.0015%, and timolol 0.5% for the treatment of open-angle glaucoma (OAG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Value-Based Medicine\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , incremental cost-utility analysis, and average cost-utility analysis were performed using published systematic review and network meta-analyses with 3-month clinical data for a base case of OAG with an untreated intraocular pressure of 26\u2009mm Hg. Visual acuity and visual field changes were converted to time tradeoff utility format. A 20-year model was undertaken; bilateral therapy was presumed; a national average Medicare Fee Schedule was used; and ophthalmic, third party insurer, and societal cost perspectives were utilized. Patient value outcomes (QALYs or quality-adjusted life-years) and costs were discounted at 3% annually.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Bimatoprost conferred a mean 2.56 QALY gain (22.9% patient quality-of-life gain) for the average OAG patient, while latanoprost for the average OAG patient, while latanoprost conferred a 2.00 QALY gain (17.8% quality-of-life gain), tafluprost a 1.99 QALY gain (17.9% quality-of-life gain), travoprost a l.92 QALY gain (17.2% quality-of-life gain), and timolol a 1.42 QALY gain (12.8% quality-of-life gain). The ophthalmic cost-perspective, incremental cost-utility ratio of bimatoprost referent to travoprost was $6,034\/QALY, to latanoprost was $27,973\/QALY, and to timolol was $16,063\/QALY. Bimatoprost dominated tafluprost, meaning that it conferred greater patient value for lesser cost than tafluprost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Topical bimatoprost delivers greater patient value than the other prostamides and topical timolol for the treatment of OAG. Bimatoprost is incrementally cost-effective referent to the other prostamides and timolol.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2018.0114","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T10:50:31Z","timestamp":1553770231000},"page":"145-160","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostamides for Open-Angle Glaucoma"],"prefix":"10.1177","volume":"35","author":[{"given":"Gary C.","family":"Brown","sequence":"first","affiliation":[{"name":"Center for Value-Based Medicine, \u00ae, Hilton Head, South Carolina."},{"name":"Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania."},{"name":"The Eye Research Institute, Philadelphia, Pennsylvania."},{"name":"Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa M.","family":"Brown","sequence":"additional","affiliation":[{"name":"Center for Value-Based Medicine, \u00ae, Hilton Head, South Carolina."},{"name":"Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania."},{"name":"The Eye Research Institute, Philadelphia, Pennsylvania."},{"name":"Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,4,6]]},"reference":[{"key":"e_1_3_5_2_2","first-page":"688","article-title":"and XLT Study Group","volume":"135","author":"Parrish R.K.","year":"2003","unstructured":"Parrish R.K., , Palmberg P., , Sheu WP; and XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol. 135:688\u2013703, 2003.","journal-title":"A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.85.8.962"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.04.006"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.06.030"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.01.040"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.08.041"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702964"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210801800206"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01437-9"},{"key":"e_1_3_5_11_2","first-page":"129","article-title":"Comparative effectiveness of first-line medications for primary open-angle glaucoma","volume":"123","author":"Li T.","year":"2016","unstructured":"Li T., , Lindsley K., , Rouse B., et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma. A systematic review and network meta-analysis. Ophthalmology., 123:129\u2013140, 2016.","journal-title":"A systematic review and network meta-analysis. Ophthalmology."},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-7-16"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X280626"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.2727"},{"key":"e_1_3_5_15_2","first-page":"008","article-title":"Cost-utility analysis of timolol for the treatment for open-angle glaucoma","volume":"1","author":"Brown G.C.","year":"2015","unstructured":"Brown G.C., , Stein J.D., , Brown M.M., et al. Cost-utility analysis of timolol for the treatment for open-angle glaucoma. J. Ophthalmol. 1:008, 2015.","journal-title":"J. Ophthalmol"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/IEB.0b013e3182049394"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-4182(00)80005-8"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725040-00003"},{"key":"e_1_3_5_19_2","first-page":"151","volume-title":"Evidence-Based to Value-Based Medicine","author":"Brown M.M.","year":"2005","unstructured":"Brown M.M., , Brown G.C., , and Sharma S. Evidence-Based to Value-Based Medicine. Chicago, AMA Press; 2005, pp. 151\u2013265."},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(02)00457-5"},{"key":"e_1_3_5_21_2","first-page":"285","article-title":"Value-Based Medicine","volume":"18","author":"Brown M.M.","year":"2006","unstructured":"Brown M.M., , Brown G.C., , and Sharma S. Value-Based Medicine. A paradigm for quality pharmaceutical care. Drug Benefit Trends., 18:285\u2013289, 2006.","journal-title":"A paradigm for quality pharmaceutical care. Drug Benefit Trends."},{"key":"e_1_3_5_22_2","first-page":"2367","article-title":"Cataract surgery cost-utility revisited in 2012","volume":"120","author":"Brown G.C.","year":"2013","unstructured":"Brown G.C., , Brown M.M., , Menezes A., et al. Cataract surgery cost-utility revisited in 2012. A new economic paradigm. Ophthalmology., 120:2367\u20132376, 2013.","journal-title":"A new economic paradigm. Ophthalmology."},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.032"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.77.3.176"},{"key":"e_1_3_5_25_2","unstructured":"World Health Organization. Change the definition of blindness. From the internet @ www.who.int\/blindness\/Change%20the%20Definition%20of%20Blindness.pdf (accessed September26 2018)."},{"key":"e_1_3_5_26_2","first-page":"473","article-title":"Vision and quality of life","volume":"97","author":"Brown G.C.","year":"1999","unstructured":"Brown G.C. Vision and quality of life. Trans. Am. Ophthalmol. Soc. 97:473\u2013512, 1999.","journal-title":"Trans. Am. Ophthalmol. Soc"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.85.3.327"},{"key":"e_1_3_5_28_2","first-page":"365","article-title":"Progression of visual field loss in untreated glaucoma patients and suspects in St Lucia, West Indies","volume":"10","author":"Wilson M.R.","year":"2002","unstructured":"Wilson M.R., , Kosoko O., , Cowan Jr., C.L., et al. Progression of visual field loss in untreated glaucoma patients and suspects in St Lucia, West Indies. Trans. Am. Ophthalmol. Soc. 10:365\u2013410, 2002.","journal-title":"Trans. Am. Ophthalmol. Soc"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.04.007"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.07.012"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.06.042"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.07.044"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.12.003"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.10.004"},{"key":"e_1_3_5_35_2","first-page":"1177","article-title":"Intraocular pressure-lowering effects of all commonly used glaucoma drugs","volume":"112","author":"van der Valk R.","year":"2005","unstructured":"van der Valk R., , Webers V.A.B., , Shouten J.S.A, .G., Zeegers M.P., , Hendrickse F., , and Prins M.H. Intraocular pressure-lowering effects of all commonly used glaucoma drugs. A meta-analysis of randomized clinical trials. Ophthalmology., 112:1177\u20131185, 2005.","journal-title":"A meta-analysis of randomized clinical trials. Ophthalmology."},{"key":"e_1_3_5_36_2","unstructured":"Center for Drug Evaluation and Research. Applications number 202514Orig1s000. Medical Review(s) for tafluprost. From the Internet @ www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202514Orig1s000MedR.pdf (accessed November1 2018)."},{"key":"e_1_3_5_37_2","unstructured":"U.S. Food and Drug Administration. Travoprost ophthalmic solution 0.004%. NDA 21-257 Medical Review. From the Internet @ www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21257_Travatan_medr_P1.pdf (accessed September5 2018)."},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S89904"},{"key":"e_1_3_5_39_2","unstructured":"U.S. Food and Drug Administration. Latanoprost ophthalmic solution 0.3%. Full Prescribing information. From the Internet @ www.accessdata.fda.gov\/drugsat.fda_docs\/label\/2017\/020597s051lbl.pdf (accessed September5 2018)."},{"key":"e_1_3_5_40_2","first-page":"9","article-title":"United States Life Tables, 2014","volume":"66","author":"Arias E.","year":"2017","unstructured":"Arias E., , Heron M., , and Xu J. United States Life Tables, 2014. Natl. Vital Stat. Rep. 66:9\u201310, 2017.","journal-title":"Natl. Vital Stat. Rep"},{"key":"e_1_3_5_41_2","unstructured":"AWP Value Rx Card. Average Wholesale Price. From the Internet @ http:\/\/awpvaluerx.com\/drugpricing.htm (accessed November6 2015)."},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7377.1396"},{"key":"e_1_3_5_43_2","first-page":"2","article-title":"Improper topical self-administration of ocular medication among patients with glaucoma","volume":"19","author":"Brown M.M.","year":"1984","unstructured":"Brown M.M., , Brown G.C., , and Spaeth G.L. Improper topical self-administration of ocular medication among patients with glaucoma. Can. J. Ophthalmol. 19:2\u20135, 1984.","journal-title":"Can. J. Ophthalmol"},{"key":"e_1_3_5_44_2","unstructured":"CMS.gov. Physician Fee Schedule Search. From the Internet @ www.cms.gov\/apps\/physician-fee-schedule\/search\/search-criteria.aspx (accessed December16 2015)."},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.07.054"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000717"},{"key":"e_1_3_5_47_2","unstructured":"Bureau of Labor and Statistics. Employer costs for employee compensation. From the Internet @ www.bls.gov\/news.release\/pdf\/ecec.pdf (accessed October10 2015)."},{"key":"e_1_3_5_48_2","first-page":"159","article-title":"Guidelines for pharmacoeconomic studies","volume":"11","author":"Siegel J.E.","year":"1997","unstructured":"Siegel J.E., , Torrance G.W., , Russell L.B., , Luce B.R., , Weinstein M.C., , and Gold M.R. Guidelines for pharmacoeconomic studies. Recommendations from the Panel on Cost Effectiveness in Health and Medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics. 11:159\u2013168, 1997.","journal-title":"Recommendations from the Panel on Cost Effectiveness in Health and Medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.4.532"},{"key":"e_1_3_5_50_2","unstructured":"Centers for Disease Control and Prevention. Health insurance coverage of noninstitutionalized Medicare beneficiaries aged 65 and over by type of coverage and selected characteristics: United States selected years 1992\u20132013 Table 106. From the Internet @ www.cdc.gov\/nchs\/data\/hus\/2016\/106.pdf (accessed September2 2018)."},{"key":"e_1_3_5_51_2","unstructured":"Smith J.C. Medalla C; and for the United States Census Bureau. Health insurance coverage in the United States: 2014. Current Population Report. From the Internet @ www.census.gov\/content\/dam\/Census\/library\/publications\/2015\/demo\/p60-253.pdf (accessed November10 2015)."},{"key":"e_1_3_5_52_2","unstructured":"Cubanski J. Swoope C. Boccuti C. Jacobson G. Casillas G. Griffin S. and Neuman T. A Primer on Medicare: Key Facts About the Medicare Program and the People it Covers. From the Internet @ www.kff.org\/report-section\/a-primer-on-medicare-what-types-of-supplemental-insurance-do-beneficiaries-have\/ (accessed September1 2018)."},{"key":"e_1_3_5_53_2","unstructured":"Henry J; and Kaiser Family Foundation. Nursing Facilities Staffing Residents and Facility Deficiencies 2009 Through 2016. From the Internet @ http:\/\/kff.org\/medicaid\/fact-sheet\/overview-of-nursing-facility-capacity-financing-and-ownership-in-the-united-states-in-2011\/ (accessed September12 2018)."},{"key":"e_1_3_5_54_2","unstructured":"Central Intelligence Agency. The World Factbook. From the Internet @ www.cia.gov\/library\/publications\/the-world-factbook\/rankorder\/2004rank.html (accessed September27 2018)."},{"key":"e_1_3_5_55_2","unstructured":"ICD10Data.com. Legal blindness as defined in USA. From the Internet @ www.icd10data.com\/ICD10CM\/Codes\/H00-H59\/H53-H54\/H54-\/H54.8 (accessed September10 2018)."},{"key":"e_1_3_5_56_2","first-page":"319","volume-title":"Panel on Cost-Effectiveness in Health and Medicine","author":"Brock D.W.","year":"2017","unstructured":"Brock D.W., , Daniels N., , Neumann P.J., , and Siegel J.E. Ethical and distributive considerations. In: Neumann P.J., , Sanders G.D., , Russell L.B., et al. eds. Panel on Cost-Effectiveness in Health and Medicine. Second edition. New York, Oxford University Press, 2017, pp. 319\u2013327."},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.127407"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2018.0114","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2018.0114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2018.0114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:42:54Z","timestamp":1777646574000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2018.0114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4,1]]}},"alternative-id":["10.1089\/jop.2018.0114"],"URL":"https:\/\/doi.org\/10.1089\/jop.2018.0114","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}